Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 15/20 | 0.65 |
| ▸ | NMUR1 | Q9HB89 | 14/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31588354 | 0.88 | OPRM1 (0.61) | NMUR2NMUR1EPHA2NTSR2NTSR1 | |
| SCHEMBL31307220 | 0.88 | NMUR2 (0.60) | NMUR2NMUR1 | |
| SCHEMBL8808129 | 0.88 | NMUR2 (0.70) | NMUR2NMUR1 | |
| SCHEMBL8808113 | 0.88 | NMUR2 (0.70) | NMUR2NMUR1 | |
| SCHEMBL30564574 | 0.88 | NMUR2 (0.61) | NMUR2NMUR1EPHA2NTSR2NTSR1 | |
| SCHEMBL30680640 | 0.87 | NMUR2 (0.61) | NMUR2NMUR1EPHA2NTSR2NTSR1 | |
| SCHEMBL30168766 | 0.86 | NMUR2 (0.68) | NMUR2NMUR1EPHA2 | |
| SCHEMBL30634740 | 0.86 | NMUR2 (0.65) | NMUR2NMUR1EPHA2NTSR2NTSR1 | |
| SCHEMBL30956237 | 0.85 | NPY1R (0.70) | NMUR2NMUR1NTSR2NTSR1 | |
| SCHEMBL9807235 | 0.85 | EPHA2 (0.64) | NMUR2NMUR1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
| EP-1409017-A4 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1409017-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | Drug Innovation & Design, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | DRUG INNOVATION & DESIGN, INCORPORATED | 2003-02-13 | — | — | US | disclosed |
| WO-2003000201-A2 | EXPONENTIAL PATTERN RECOGNITION BASED CELLULAR TARGETING, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS | DRUG INNOVATION & DESIGN, INCORPORATED (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030031677-A1 | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications | EPHA2, EEA1, TPX2 | NMUR2 2114/4885NMUR1 2812/4885EPHA2 1/4885 |
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | NMUR2 2009/4885NMUR1 2689/4885EPHA2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.